ROARABLE
FREE $100K
My Trading Account →
▾
Trading Account Active
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / AURA
IAM (47) CADL (33) FDMT (44) SLDB (26) ⌘ Pro Terminal →

Aura Biosciences Inc. (AURA) — RQD Stock Rating Cockpit

$6.03 -1.79% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $6.00

Aura Biosciences Inc. (AURA) carries a Roarable Rating of E (Strong Sell) with 29/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $636.7M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AURA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Aura Biosciences Inc. (NASDAQ: AURA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $6.03 (-1.79% 1D, market cap $636.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, AURA ranks #822 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AURA compare to IAM and CADL in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AURA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IAM (Iambic Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $636.6M) and CADL (Candel Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $637.4M). Among the 5-stock peer group, AURA leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AURA?
▼

Per AURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001501796), Aura Biosciences Inc. generated $315.8M in revenue (+17.3% YoY), -$106.2M in net income, and -$85.2M in free cash flow against $169.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $6.00 (-0.51%)🧬 Dilution Drag (+2.48% YoY Shares)⚙️ Cash Engine: 7/20 (D-) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (29/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-9.8% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510029
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk D-
Cash (7)Whales (4)SEC (10)Macro (5)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-13.1% Base Target
$10 Bull$5 Base$4 Bear
📬 FREE AURA RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AURA)Realized 20D OHLCV Swing Band: ±9.3%
Deterministic 5-Pillar Attribution (29/100 Composite)
🔍 WHY AURA SCORES 29/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (34% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9

▲ #2 Bullish Driver: Cash Engine Quality+7/20 pts (24% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 52% Gross Margin

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
37
Grade E$6.27+4.6% Next Q
Q2 (-2Q)
34
Grade E$6.56-4% Next Q
Q3 (-1Q)
32
Grade E$6.30-4.3% Next Q
Current
29
Grade E$6.03-9.8% Hist 90D α
Trajectory: E (37) → E (29)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a AURA Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While AURA currently carries a cautious 29/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($6.62) and Max Pain ($6.33) forces dealer call-delta covering toward $10.01.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AURA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AURA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 29%NO 71%Trade / Inspect Odds →
RSI-14 MOMENTUMNEUTRAL RANGE
43.530 Oversold · 70 Hot
ALTMAN-Z SHIELDFORTRESS SAFE (>3.0)
3.80>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
2 / 99-Pt Accounting
52-WEEK LASER RANGE27% OF RANGE
L: $5$6.03H: $10
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: D-RQD 7 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 7 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: D-RQD 15 / 40
MULTI-MODEL JEV QUANT JURY DELIBERATION

3-of-3 JEV AI Jury Bearish Warning on AURA

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (35)

-35.0% ROIC with 42.0% gross margin and -13.05% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (50)

Altman-Z 4.20 and Piotroski 2/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (20)

7/40 institutional & smart-money positioning score with 5/20 macro alignment.

Bull Case: Why Buyers Like AURA
  • ✓Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AURA)

  • ✓Walkthrough of AURA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AURA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -27.78%▼ DESCENDING CHANNEL
2026-11-03O $6.29H $6.29L $6.03C $6.03VOL 533.0K
RES: $6.40SUP: $5.31SMA50: $6.62SMA200: $6.73
$9.78$8.74$7.70$6.67$5.63RES $6.40SUP $5.31$6.032026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AURA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AURA Butterfly Map → + Track AURA →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +17.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AURA today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AURA. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AURA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AURA)

Health Care Rank #822 of 1015 ⚔️ IAM vs AURA Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AURA vs. IAM, CADL, FDMT, SLDB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Aura Biosciences Inc. (AURA) ranks #822 by composite RQD confidence (29/100, grade E) and #405 by equity capitalization ($636.7M). Within this direct 5-issuer industry benchmark cohort, AURA leads on earnings valuation at N/A trailing P/E, while FDMT leads on capital efficiency and profitability with -28.3% ROIC and — gross margin. IAM currently holds the highest overall quantitative score in the immediate peer group at 47/100 (D) compared with AURA at 29/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AURA ACTIVE
Aura Biosciences Inc.
E 29/100 — — -35.0% -1.79% $636.7M Benchmark Subject
IAM
Iambic Therapeutics Inc.
D 47/100 — — — -3.54% $636.6M /iam-vs-aura →
CADL
Candel Therapeutics Inc.
E 33/100 — — -35.0% -2.52% $637.4M /cadl-vs-aura →
FDMT
4D Molecular Therapeutics Inc.
D 44/100 — — -28.3% -4.45% $657.4M /fdmt-vs-aura →
SLDB
Solid Biosciences Inc.
E 26/100 — — -35.0% -3.23% $664.8M /sldb-vs-aura →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001501796 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Aura Biosciences Inc. (AURA) reported GAAP revenue of $315.8M (+17.3% vs. FY2024 revenue of $269.1M , and +32.7% cumulative change since FY2023) , GAAP net income of -$106.2M, operating cash flow of -$84.7M, and free cash flow of -$85.2M (-5.1% YoY). On the balance sheet, AURA closed FY2025 with $169.4M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $315.8M -$106.2M -$84.7M -$85.2M $169.4M —
FY2024 (FY) 2024-12-31 $269.1M -$86.9M -$79.8M -$81.1M $182.5M —
FY2023 (FY) 2023-12-31 $238.0M -$76.4M -$63.8M -$63.8M — —

3. AURA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AURA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Aura Biosciences Inc. (NASDAQ: AURA) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 29/100 at a spot price of $6.03 (-1.79% 1D, market cap $636.7M). Pillar breakdown: Fundamental Cash Engine 7/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 10/20, FRED Macro Regime Fit 5/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, AURA ranks #822 in composite RQD confidence.

How does AURA compare to IAM and CADL in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), AURA carries a Roarable E (29/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, IAM (Iambic Therapeutics Inc.) holds a D grade (47/100 RQD, P/E N/A, ROIC —, cap $636.6M) and CADL (Candel Therapeutics Inc.) posts a E grade (33/100 RQD, P/E N/A, ROIC -35.0%, cap $637.4M). Among the 5-stock peer group, AURA leads on earnings multiple (N/A) while FDMT leads on capital efficiency (-28.3% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AURA?

Per AURA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001501796), Aura Biosciences Inc. generated $315.8M in revenue (+17.3% YoY), -$106.2M in net income, and -$85.2M in free cash flow against $169.4M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AURA trading relative to its 50-day, 200-day, and 52-week technical levels?

AURA last traded at $6.03 (-1.79% on volume of 746,593 shares), positioning the stock -8.91% below its 50-day simple moving average ($6.62) and -10.40% below its 200-day simple moving average ($6.73). Across its 52-week range of $4.73 to $9.53, AURA sits at the 27.1% percentile with a 14-day RSI of 43.5 (NEUTRAL RANGE) and an implied next-earnings move of ±9.3% ($5.47 to $6.59).

Direct Sub-Reports: AURA RQD Cockpit AURA 12M Forecast AURA Earnings & Move AURA Dividends & DRIP AURA Insiders & 13F AURA Whale Options AURA Profit Sankey AURA News & Why
ROARABLE RATING BRIEF • RQD 29/100 (E) ✓ SEC XBRL & RQD VERIFIED

AURA — Aura Biosciences Inc.: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Aura Biosciences Inc. (AURA) earns a live Roarable RQD composite score of 29/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $6.03 (-1.79% 1D, market capitalization $636.7M).

  • Fundamental Cash Engine (7/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of —, operating margin of —, and free cash flow yield of -13.05%.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (5/20) + Forensic Balance Sheet (10/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 2/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Aura Biosciences Inc. Is a NASDAQ-listed issuer in the Health Care sector, operating in Biotechnology: Biological Products (No Diagnostic Substances). Reported revenue is — across the FY 2023, FY 2024, and FY 2025 periods .

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Aura Biosciences Inc. (AURA) reported $315.8M in annual revenue (up from $269.1M in FY2024, +17.3% YoY) and -$106.2M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($238.0M revenue, -$76.4M net income) through FY2025, AURA scaled operating cash flow to -$84.7M and free cash flow to -$85.2M, backed by $169.4M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 29/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of -13.05% and institutional whale pillar of 4/20. With Fundamental Cash Engine at 7/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $4.73 – $9.53 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against — operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

No upstream or downstream dependencies, sector correlations, or bottleneck links are recorded.

  • Key Question #1: Can AURA sustain or expand its — operating margin and -35.0% ROIC against Biotechnology: Biological Products (No Diagnostic Substances) peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $315.8M and free cash flow of -$85.2M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is AURA's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

AURA Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Aura Biosciences Inc. (AURA) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AURA Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AURA Bull vs. Bear Conversation Board — What's Your Call at $6.03?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AURA 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AURA:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
TA TapeReader_Pro RQD DEBATE OPENER • Price Action & Volume Trader 🐂 BULLISH 🎯 Target: $7.86 (+28.0%)
📌 Pinned Debate

Balance sheet pillar is the relative strength at 10 / 20, with Altman Z 2.5 and Debt/Equity 0.5, and the news wire flags a pivotal tria

Picked up a starter position in AURA in my $100K Virtual Cash book at $6.14. Balance sheet pillar is the relative strength at 10 / 20, with Altman Z 2.5 and Debt/Equity 0.5, and the news wire flags a pivotal trial.. Trading inside a $4.73–$9.53 52-week range with -13.05% FCF yield gives solid downside support if Biotechnology: Biological Products (No Diagnostic Substances) multiples expand this quarter.

CapAlloc_Nerd 🐂 BULL

@TapeReader_Pro Agree on the RQD 29/100 quality, though with 1.0 beta I'm scaling in with half-size at $6.14 and keeping dry powder in case we test $5.71.

RI RiskArb_Desk RQD DEBATE OPENER • Hedged Event Driven 🐻 BEARISH 🎯 Target: $4.67 (-23.9%)
Spot @ $6.14

Negative ROIC of -35%, negative FCF yield of -13.05%, and operating losses that widened to -$112.8M in FY 2025 with zero reported reven

Fading this rally in AURA at $6.14. Negative ROIC of -35%, negative FCF yield of -13.05%, and operating losses that widened to -$112.8M in FY 2025 with zero reported revenue.. With a beta of 1.0 and the stock sitting at $6.14 (52-wk range $4.73–$9.53), the easy multiple expansion is already priced in.

LIVE TAPE